CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Lyra Therapeutics, Inc. - LYRA CFD

3.74
4.95%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.20
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Lyra Therapeutics Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 3.84
Open* 3.73
1-Year Change* -25.25%
Day's Range* 3.65 - 3.73
52 wk Range 1.86-6.48
Average Volume (10 days) 48.27K
Average Volume (3 months) 3.39M
Market Cap 186.79M
P/E Ratio -100.00K
Shares Outstanding 49.55M
Revenue 1.24M
EPS -1.59
Dividend (Yield %) N/A
Beta -0.14
Next Earnings Date Nov 6, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Oct 3, 2023 3.84 0.07 1.86% 3.77 3.93 3.71
Oct 2, 2023 3.82 0.04 1.06% 3.78 3.88 3.71
Sep 29, 2023 3.87 0.08 2.11% 3.79 4.02 3.62
Sep 28, 2023 3.86 0.16 4.32% 3.70 4.01 3.66
Sep 27, 2023 3.68 -0.10 -2.65% 3.78 3.95 3.63
Sep 26, 2023 3.76 0.08 2.17% 3.68 3.88 3.49
Sep 25, 2023 3.70 0.12 3.35% 3.58 3.80 3.48
Sep 22, 2023 3.64 -0.55 -13.13% 4.19 4.28 3.46
Sep 21, 2023 4.34 0.06 1.40% 4.28 4.44 4.17
Sep 20, 2023 4.37 -0.32 -6.82% 4.69 4.76 4.17
Sep 19, 2023 4.79 0.23 5.04% 4.56 4.81 4.55
Sep 18, 2023 4.55 0.38 9.11% 4.17 4.68 4.13
Sep 15, 2023 4.33 -0.31 -6.68% 4.64 4.77 4.30
Sep 14, 2023 4.72 0.13 2.83% 4.59 5.01 4.59
Sep 13, 2023 4.65 0.21 4.73% 4.44 4.95 4.42
Sep 12, 2023 4.55 -0.18 -3.81% 4.73 4.89 4.30
Sep 11, 2023 4.22 0.38 9.90% 3.84 4.26 3.78
Sep 8, 2023 3.78 0.12 3.28% 3.66 3.91 3.58
Sep 7, 2023 3.74 0.24 6.86% 3.50 3.83 3.37
Sep 6, 2023 3.55 0.07 2.01% 3.48 3.60 3.37

Lyra Therapeutics, Inc. Events

Time (UTC) Country Event
Monday, November 6, 2023

Time (UTC)

10:59

Country

US

Event

Q3 2023 Lyra Therapeutics Inc Earnings Release
Q3 2023 Lyra Therapeutics Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 1.363 0.285 0 0 1.244
Revenue 1.363 0.285 0 1.244
Total Operating Expense 57.669 43.9 22.209 16.519 8.503
Selling/General/Admin. Expenses, Total 17.556 14.206 9.687 4.487 3.528
Research & Development 38.797 29.694 12.522 12.032 4.975
Operating Income -56.306 -43.615 -22.209 -16.519 -7.259
Interest Income (Expense), Net Non-Operating 1.041 0.102 0.082 0.213 0.036
Other, Net 0 1.194
Net Income Before Taxes -55.265 -43.513 -22.127 -16.306 -6.029
Net Income After Taxes -55.278 -43.513 -22.127 -16.306 -6.029
Net Income Before Extra. Items -55.278 -43.513 -22.127 -16.306 -6.029
Net Income -55.278 -43.513 -22.127 -16.306 -6.029
Income Available to Common Excl. Extra. Items -55.278 -43.513 -22.242 -16.306 -6.029
Income Available to Common Incl. Extra. Items -55.278 -43.513 -22.242 -16.306 -6.029
Diluted Net Income -55.278 -43.513 -22.242 -16.306 -6.029
Diluted Weighted Average Shares 30.2357 12.9861 8.59021 12.3996 12.3996
Diluted EPS Excluding Extraordinary Items -1.82824 -3.35074 -2.58923 -1.31505 -0.48623
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -1.79995 -3.35074 -2.58923 -1.31505 -0.48623
Total Adjustments to Net Income -0.115
Unusual Expense (Income) 1.316
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0.458 0.41 0.011 0.359 0.993
Total Operating Expense 16.961 17.723 15.166 15.185 27.318
Selling/General/Admin. Expenses, Total 4.57 5.127 4.399 5.137 8.02
Research & Development 10.799 12.596 9.451 10.048 19.298
Operating Income -16.503 -17.313 -15.155 -14.826 -26.325
Interest Income (Expense), Net Non-Operating 0.897 1.072 0.933 0.06 0.048
Net Income Before Taxes -15.606 -16.241 -14.222 -14.766 -26.277
Net Income After Taxes -15.618 -16.255 -14.235 -14.766 -26.277
Net Income Before Extra. Items -15.618 -16.255 -14.235 -14.766 -26.277
Net Income -15.618 -16.255 -14.235 -14.766 -26.277
Total Adjustments to Net Income
Income Available to Common Excl. Extra. Items -15.618 -16.255 -14.235 -14.766 -26.277
Income Available to Common Incl. Extra. Items -15.618 -16.255 -14.235 -14.766 -26.277
Diluted Net Income -15.618 -16.255 -14.235 -14.766 -26.277
Diluted Weighted Average Shares 43.6764 36.8327 36.8994 36.8264 32.4204
Diluted EPS Excluding Extraordinary Items -0.35758 -0.44132 -0.38578 -0.40096 -0.81051
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.33389 -0.44132 -0.3626 -0.40096 -0.81051
Revenue 0.458 0.41 0.011 0.359 0.993
Unusual Expense (Income) 1.592 1.316
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 100.829 47.918 75.917 10.119 24.927
Cash and Short Term Investments 97.894 45.747 74.593 9.808 23.888
Cash & Equivalents 32.55 45.747 74.593 9.808 23.888
Total Receivables, Net 0 0.167
Prepaid Expenses 2.935 2.171 1.324 0.311 0.872
Total Assets 109.968 54.867 80.83 14.963 25.359
Property/Plant/Equipment, Total - Net 4.466 5.858 4.466 3.419 0.103
Property/Plant/Equipment, Total - Gross 8.64 9.737 7.344 6.248 2.905
Accumulated Depreciation, Total -4.174 -3.879 -2.878 -2.829 -2.802
Other Long Term Assets, Total 4.673 1.091 0.447 1.425 0.329
Total Current Liabilities 14.47 18.246 4.884 5.208 1.96
Accounts Payable 2.616 3.125 0.922 1.069 0.631
Accrued Expenses 10.579 5.332 3.962 4.139 1.329
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 29.214 20.551 6.338 7.635 2.08
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 14.744 2.305 1.454 2.427 0.12
Total Equity 80.754 34.316 74.492 7.328 23.279
Redeemable Preferred Stock 0 130.666 130.353
Common Stock 0.032 0.013 0.013 0.008 0.006
Additional Paid-In Capital 329.387 227.7 224.363 4.411 4.371
Retained Earnings (Accumulated Deficit) -248.675 -193.397 -149.884 -127.757 -111.451
Total Liabilities & Shareholders’ Equity 109.968 54.867 80.83 14.963 25.359
Total Common Shares Outstanding 31.8277 13.0072 12.9324 12.3996 12.3996
Other Current Liabilities, Total 1.275 9.789
Short Term Investments 65.344
Other Equity, Total 0.01
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 84.799 100.829 112.23 122.381 40.555
Cash and Short Term Investments 82.707 97.894 109.558 120.669 33.755
Cash & Equivalents 22.019 32.55 109.558 120.669 33.755
Prepaid Expenses 2.092 2.935 2.343 1.383 1.8
Total Assets 93.868 109.968 119.463 130.035 47.345
Property/Plant/Equipment, Total - Net 3.829 4.466 4.361 4.869 5.384
Property/Plant/Equipment, Total - Gross 8.64 9.085 9.314 9.543
Accumulated Depreciation, Total -4.174 -4.724 -4.445 -4.159
Other Long Term Assets, Total 5.24 4.673 2.872 2.785 1.406
Total Current Liabilities 14.154 14.47 13.605 10.607 21.965
Accounts Payable 3.951 2.616 2.9 1.67 2.408
Accrued Expenses 8.693 10.579 7.975 6.391 5.334
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 27.777 29.214 26.241 23.786 24.088
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 13.623 14.744 12.636 13.179 2.123
Total Equity 66.091 80.754 93.222 106.249 23.257
Common Stock 0.032 0.032 0.032 0.032 0.013
Additional Paid-In Capital 331.001 329.387 327.63 325.891 228.552
Retained Earnings (Accumulated Deficit) -264.93 -248.675 -234.44 -219.674 -205.308
Total Liabilities & Shareholders’ Equity 93.868 109.968 119.463 130.035 47.345
Total Common Shares Outstanding 31.8368 31.8277 31.827 31.8264 13.0099
Other Current Liabilities, Total 1.51 1.275 2.73 2.546 14.223
Total Receivables, Net 5
Other Current Assets, Total 0.329 0.329
Short Term Investments 60.688 65.344
Other Equity, Total -0.012 0.01
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -55.278 -43.513 -22.127 -16.306 -6.029
Cash From Operating Activities -43.385 -25.82 -21.143 -13.754 -6.64
Cash From Operating Activities 1.067 1.001 0.095 0.027 0.082
Non-Cash Items 6.271 2.77 1.768 0.411 -0.772
Changes in Working Capital 4.555 13.922 -0.879 2.114 0.079
Cash From Investing Activities -65.006 -3.385 -1.775 -0.211 -0.037
Capital Expenditures -0.164 -3.385 -1.775 -0.211 -0.037
Cash From Financing Activities 96.257 0.359 87.703 -0.115 29.213
Financing Cash Flow Items -4.246 -0.245 -2.589 -0.226 -0.299
Issuance (Retirement) of Stock, Net 100.503 0.604 90.292 0.111 29.012
Issuance (Retirement) of Debt, Net 0 0.5
Net Change in Cash -12.134 -28.846 64.785 -14.08 22.536
Other Investing Cash Flow Items, Total -64.842
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -16.255 -55.278 -41.043 -21.496 -7.012
Cash From Operating Activities -15.85 -43.385 -31.221 -20.375 -11.905
Cash From Operating Activities 0.284 1.067 0.845 0.566 0.28
Non-Cash Items 0.884 6.271 3.69 1.951 0.844
Changes in Working Capital -0.763 4.555 5.287 -1.396 -6.017
Cash From Investing Activities 5.315 -65.006 -0.136 -0.107 -0.093
Capital Expenditures -0.045 -0.164 -0.136 -0.107 -0.093
Cash From Financing Activities 0.004 96.257 96.257 96.493 0.006
Financing Cash Flow Items 0 -4.246 -4.246 -4.01 -0.002
Issuance (Retirement) of Stock, Net 0.004 100.503 100.503 100.503 0.008
Net Change in Cash -10.531 -12.134 64.9 76.011 -11.992
Other Investing Cash Flow Items, Total 5.36 -64.842

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Lyra Therapeutics, Inc. Company profile

About Lyra Therapeutics Inc

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on development and commercialization of novel drug and delivery solutions for the treatment of patients with ear, nose, and throat (ENT) diseases. Its technology platform, XTreo, is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, are bioresorbable polymeric matrices administered in a non-invasive, in-office procedure to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis (CRS). LYR-210 is an anti-inflammatory implantable drug matrix based on its XTreo platform that is designed to elute mometasone furoate (MF) to the inflamed mucosal tissue for up to six months in surgically naive CRS patients. LYR-220 is an investigative therapy for CRS patients with and without nasal polyps.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Lyra Therapeutics Inc revenues increased from $0K to $285K. Net loss applicable to common stockholders increased 96% to $43.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase from $12.3M to $29.2M (expense).

Industry: Biotechnology & Medical Research (NEC)

480 Arsenal Way
WATERTOWN
MASSACHUSETTS 02472
US

Income Statement

  • Annual
  • Quarterly

News

How to Trade The Triple Top

Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.

14:13, 27 September 2023
USA flag on the background of stock charts. Financial system in USA

Q4 lookahead: US indices starting to show signs of trouble?

US indices start to draw attention as traders focus on the outlook for Q4.

07:20, 27 September 2023

USD/JPY Climbs Towards Key Highs

USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.

11:32, 26 September 2023

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

People also watch

Oil - Crude

85.99 Price
-2.850% 1D Chg, %
Long position overnight fee 0.0520%
Short position overnight fee -0.0739%
Overnight fee time 21:00 (UTC)
Spread 0.030

BTC/USD

27,591.75 Price
+0.600% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

US100

14,681.50 Price
+0.810% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 1.8

Gold

1,824.01 Price
+0.060% 1D Chg, %
Long position overnight fee -0.0194%
Short position overnight fee 0.0112%
Overnight fee time 21:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading